Skip to main content

The Therapeutic Application of RBAC in Cancer

  • Chapter
  • First Online:
Modified Rice Bran Arabinoxylan

Abstract

Growing evidence suggests that the adaptive cytotoxic cells have prophylactic effects as they work more proficiently in the early phases of tumor development, whereas the innate cellular system acts more curatively in parallel with disease progression. However, both cellular systems depend on the balance of the innate immune system, in which the degree of pre-activation (priming) and polarity play an important role. Tumor-induced dysregulation of the innate immune system leads to decreased function of type 1 effector cells and a predominance of type 2 cells, promoting the development of tumors. Consequently, we must learn to manipulate this regulation by increasing the type 1 innate immune effector activity and diminishing the type 2 system. This balance can also play an important role in the sensitivity of tumor cells to innate effectors (such as natural killer cells), which are regulated by the expressions of stress-related receptors on tumor cells (such as MICA, MICB, or ULBP 1–3). Rice bran arabinoxylan compound (RBAC) has been shown to activate the type 1 effector cells given in doses of 10–45 mg/kg and, in a controlled clinical trial, was able to result in an evidence-based antitumor effect. Case reports suggest that a combination of RBAC with therapy modalities that increase the expression of stress-related molecules on tumor cells (using growth factor receptor inhibitors or lower doses of gemcitabine) can result in remarkable clinical results. Therefore, if we learn to better manipulate the immunoregulation using standardized RBAC together with appropriate oncological treatments, it may open new strategies in tumor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Adamska A, Domenichini A, Falasca M (2017) Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci 18:1338

    Google Scholar 

  • Badr El-Din NK, Noaman E, Ghoneum M (2008) In vivo tumor inhibitory effects of nutritional rice bran supplement MGN-3/Biobran on ehrlich carcinoma-bearing mice. Nutr Cancer 60:235–244

    CAS  Google Scholar 

  • Badr El-Din NK, Ali DA, Alaa El-Dein M, Ghoneum M (2016a) Enhancing the apoptotic effect of a low dose of paclitaxel on tumor cells in mice by arabinoxylan rice bran (MGN-3/Biobran). Nutr Cancer 68:1010–1020

    CAS  Google Scholar 

  • Badr El-Din NK, Abdel Fattah SM, Pan D, Tolentino L, Ghoneum M (2016b) Chemopreventive activity of MGN-3/Biobran against chemical induction of glandular stomach carcinogenesis in rats and its apoptotic effect in gastric cancer cells. Integr Cancer Ther 15:NP26. https://doi.org/10.1177/1534735416642287

    Article  CAS  Google Scholar 

  • Bae J-H, Kim S-J, Kim M-J, Oh S-O, Chung J-S, Kim S-H, Kang C-D (2012) Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci 103:7–16

    CAS  Google Scholar 

  • Bancroft GJ (2012) Immunity to bacteria and fungi. In: Male D, Brostoff J, Roth D, Roitt I (eds) Immunology, 8th edn. Elsevier, London / Philadelphia, pp 223–242

    Google Scholar 

  • Bang MH, Van Riep T, Thinh NT et al (2010) Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. Anticancer Res 30:5145–5151

    CAS  Google Scholar 

  • Capobianchi MR (1996) Induction of lymphomonocyte activation by HIV-1 glycoprotein gp120. Possible role in AIDS pathogenesis. J Biol Regul Homeost Agents 10:83–91

    CAS  Google Scholar 

  • Cholujova D, Jakubikova J, Sedlak J (2009) BioBran-augmented maturation of human monocyte-derived dendritic cells. Neoplasma 56:89–95

    CAS  Google Scholar 

  • Cholujova D, Jakubikova J, Czako B, Martisova M, Hunakova L, Duraj J, Mistrik M, Sedlak J (2013) MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. Cancer Immunol Immunother 62:437–445

    CAS  Google Scholar 

  • Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JMD (2012) Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother 35:629–640

    CAS  Google Scholar 

  • Doan T, Melvold R, Viselli S, Waltenbaugh C (2008) Presentation by MHC class I. In: Harvey RA, Champe PC (eds) Immunology, 1st edn. Lippincott Williams and Wilkins, Philadelphia, PA, pp 123–126

    Google Scholar 

  • Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 21:2237–2246

    CAS  Google Scholar 

  • Ghoneum M, Agrawal S (2011) Activation of human monocyte-derived dendritic cells in vitro by the biological response modifier arabinoxylan rice bran (MGN-3/Biobran). Int J Immunopathol Pharmacol 24:941–948

    CAS  Google Scholar 

  • Ghoneum M, Agrawal S (2014) MGN-3/Biobran enhances generation of cytotoxic CD8+ T cells via upregulation of DEC-205 expression on dendritic cells. Int J Immunopathol Pharmacol 27:523–530

    CAS  Google Scholar 

  • Ghoneum M, Badr El-Din NK, Fattah SMA, Tolentino L (2013) Arabinoxylan rice bran (MGN-3/Biobran) provides protection against whole-body γ-irradiation in mice via restoration of hematopoietic tissues. J Radiat Res 54:419

    CAS  Google Scholar 

  • Ghoneum M, Badr El-Din NK, Ali DA, El-Dein MA (2014) Modified arabinoxylan from rice bran, MGN-3/Biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro. Anticancer Res 34:81–87

    CAS  Google Scholar 

  • Gollapudi S, Ghoneum M (2008) MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin. Cancer Detect Prev 32:1–6

    CAS  Google Scholar 

  • Hajtó T (2017) Can a standardized plant immunomodulator (rice bran arabinoxylan concentrate/MGN-3) increase the effects of MEK and BRAF inhibitors with clinical benefit? Case report of a patient with carcinoma in biliary duct. Res Rev Insights 1:1–4

    Google Scholar 

  • Hajtó T (2018) New perspectives to improve the MHC-I unrestricted immune mechanisms against malignant tumors. Adv Clin Transl Res 2:100015

    Google Scholar 

  • Hajtó T, Horváth A, Baranyai L, Kuzma M, Perjési P (2016) Can the EGFR inhibitors increase the immunomodulatory effects of standardized plant extracts (mistletoe lectin and arabinoxylan) with clinical benefit? Case report of a patient with lung adenocarcinoma. Clin Case Reports Rev 2:456–459

    Google Scholar 

  • He S, Yin T, Li D et al (2013) Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med 11:186

    Google Scholar 

  • Itoh Y, Mizuno M, Ikeda M, Nakahara R, Kubota S, Ito J, Okada T, Kawamura M, Kikkawa F, Naganawa S (2015) A randomized, double-blind pilot trial of hydrolyzed rice bran versus placebo for radioprotective effect on acute gastroenteritis secondary to chemoradiotherapy in patients with cervical cancer. Evid Based Complement Alternat Med 2015:974390

    Google Scholar 

  • Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818

    CAS  Google Scholar 

  • Kong LY, Wilson BC, McMillian MK, Bing G, Hudson PM, Hong JS (1996) The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. Cell Immunol 172:77–83

    CAS  Google Scholar 

  • Male D, Brostoff J, Roth DB, Roitt I (2013) Immunity to cancer. In: Hyde M, Vosburgh A (eds) Immunology. Elsevier, pp 355–365

    Google Scholar 

  • Mantovani A (2007) Inflammation and cancer: the macrophage connection. Medicina (B Aires) 67:32–34

    CAS  Google Scholar 

  • Martinez-Pomares L (2012) Mononuclear phagocytes in immune defense. In: Male D, Brostoff J, Roth D, Roitt I (eds) Immunology, 8th edn. Elsevier, London, pp 125–142

    Google Scholar 

  • McDermott C, Richards SCM, Thomas PW, Montgomery J, Lewith G (2006) A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. QJM 99:461–468

    CAS  Google Scholar 

  • Morisaki T, Hirano T, Koya N, Kiyota A, Tanaka H, Umebayashi M, Onishi H, Katano M (2014) NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res 34:4529–4538

    CAS  Google Scholar 

  • Murray JS (1998) How the MHC selects Th1/Th2 immunity. Immunol Today 19:157–163

    CAS  Google Scholar 

  • Okita R, Wolf D, Yasuda K et al (2015) Contrasting effects of the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells. PLoS One 10:e0139809

    Google Scholar 

  • Pérez-Martínez A, Valentín J, Fernández L et al (2015) Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo. Cytotherapy 17:601–612

    Google Scholar 

  • Sánchez-Torres C, García-Romo GS, Cornejo-Cortés MA, Rivas-Carvalho A, Sánchez-Schmitz G (2001) CD16+ and CD16− human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 13:1571–1581

    Google Scholar 

  • Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455–464

    CAS  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    CAS  Google Scholar 

  • Smith MP, Wellbrock C (2016) Molecular pathways: maintaining MAPK inhibitor sensitivity by targeting nonmutational tolerance. Clin Cancer Res 22:5966–5970

    CAS  Google Scholar 

  • Srivastava PK (2012) Immunity of cancer. In: Male D, Brostoff J, Roth D, Roitt I (eds) Immunology, 8th edn. Elsevier, London, pp 355–368

    Google Scholar 

  • Tan BL, Norhaizan ME (2017) Scientific evidence of rice by-products for cancer prevention: chemopreventive properties of waste products from rice milling on carcinogenesis in vitro and in vivo. Biomed Res Int 2017:1–18

    Google Scholar 

  • Trovato R, Fiore A, Sartori S et al (2019) Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer 7:255

    Google Scholar 

  • Xie X, Zhou Y, Wang X, Guo J, Li J, Fan H, Dou J, Shen B, Zhou C (2017) Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo. Carbohydr Polym 173:360–371

    CAS  Google Scholar 

  • Yang L, Shen M, Xu LJ, Yang X, Tsai Y, Keng PC, Chen Y, Lee SO (2017) Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. Sci Rep 7:7958

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tibor Hajto .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hajto, T. (2023). The Therapeutic Application of RBAC in Cancer. In: Pak, S.C., Ooi, S.L., Micalos, P.S., Ghoneum, M.H. (eds) Modified Rice Bran Arabinoxylan . Springer, Singapore. https://doi.org/10.1007/978-981-19-5735-2_6

Download citation

Publish with us

Policies and ethics